← Leaderboards
Adriana Haimovitz-Friedman
Sloan-Kettering Institute For Cancer Res
$1,571,443
Attributed
$1,571,443
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $319.4K · FY2005–09$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$1,571,443 · 1
By mechanism
R01$1,571,443 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Institute For Cancer Res
Same institution · by research overlap
- Glenn Heller$7,155,475
- Ulrich G Hammerling$5,628,873
- C. Thomas Powell$624,472
- Samuel J Danishefsky$25,022,733
- Derek S Tan$22,003,139
Others in their field
Top investigators on “Irradiation”
- J. Mark Cline · Wake Forest University$49,621,390
- Walter John Curran · Thomas Jefferson University$26,641,549
- Hans-Peter Kiem · Fred Hutchinson Cancer Center$26,572,036
- Samuel Strober · Stanford University$25,778,911
- Ehud Isacoff · University Of California Berkeley$23,946,000
- David Jonathan Brenner · Columbia University Health Sciences$22,934,756
Research focus
IrradiationAnimalsAcetatesIn VivoApoptoticAtaxia Telangiectasia Mutated ProteinAnimal ModelAtm GeneApoptosisBaseCancer CellCell DeathCell LineCellsCeramidesCitrate CarrierClinical ApplicationDihydroceramide DesaturaseAtm Wt AlleleDoseEnzymesGenerationsInduction Of ApoptosisIsoenzymes
Grant awards (5)
Ceramide synthase as a therapy target in prostate cancer$319,439
R01 · FY2009 · CA · contact PI
Ceramide synthase as a therapy target in prostate cancer$319,439
R01 · FY2008 · CA · contact PI
Ceramide synthase as a therapy target in prostate cancer$319,439
R01 · FY2007 · CA · contact PI
Ceramide synthase as a therapy target in prostate cancer$305,931
R01 · FY2006 · CA · contact PI
Ceramide synthase as a therapy target in prostate cancer$307,195
R01 · FY2005 · CA